Skip to content

Effects of treatment expectation towards transcranial magnetic stimulation in major depressive disorder

Effects of treatment expectation towards transcranial magnetic stimulation in major depressive disorder - Treatment expectation TMS Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00028017
Enrollment
60
Registered
2022-03-07
Start date
2022-06-13
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate depressive episode, severe depressive episode

Interventions

Group 1: Group of patients receiving a boostered medical consultation. Group 2: Group of patients gives their usual informed consent.

Sponsors

LVR-Klinikum Essen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 69 Years

Inclusion criteria

Inclusion criteria: o Age from 18 to 69 years o moderate or severe depressive episode (according to Hamilton Rating Scale for Depression, HDRS) o at least 2 unsuccessful antidepressant medication attempts in the history of the current episode

Exclusion criteria

Exclusion criteria: o Incapacitated persons and persons in official or judicial custody. o Persons with consumptive diseases and/or in poor general condition o No sufficient hearing or reading ability o Contraindications for rTMS presence of ferromagnetic material (e.g. cochlear implants) in the brain Pregnancy Cardiac pacemaker Epilepsy o previous rTMS treatment o electroconvulsive therapy in the preceding 6 months o relevant structural lesions on MRI: this excludes expected age-related changes such as mild cerebral microangiopathy in patients over 50 years of age or changes without expected relevance such as small arachnoid cyst o Relevant comorbidities Current substance abuse or dependence Organic mental disorders Dementia Schizophrenia and schizoaffective disorder Neurological disorders, e.g., multiple sclerosis, Parkinson's syndrome (excluding headache disorders) Diseases that are associated with an inflammatory response and lead to permanently elevated inflammatory parameters Severe internal diseases associated with a significantly reduced general condition

Design outcomes

Primary

MeasureTime frame
Therapy success. Measurement: questionnaires.

Secondary

MeasureTime frame
therapy success. Measurement: cognitive tests, MRI, blood sampes, salive samples

Countries

Germany

Contacts

Public ContactKatharina Marie Steiner

LVR-Klinikum Essen

katharinamarie.steiner@uk-essen.de004920172270

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 8, 2026